Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Plus Cetuximab and Chemotherapy for RAS/BRAF Wild-Type mCRC with Liver Metastases
NCT06231017Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in colorectal cancer (CRC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective Response Rate at 1 year. Started Jan 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06231017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231017.